PRINCETON, N.J., June 7 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that it is scheduled to present at the Sixth
Annual Needham Biotechnology and Medical Technology Conference at 8:30 AM
Eastern Time on Thursday, June 14, 2007. The conference is being held at
The New York Palace in New York City. Medarex's presentation will be
webcast live and will be available for replay through the Webcasts page in
the Investor Relations section of the Medarex website via the Internet at
http://www.medarex.com.
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 30 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with six of the most advanced product candidates currently
in Phase III clinical trials. Medarex is committed to building value by
developing a diverse pipeline of antibody products to address the world's
unmet healthcare needs. For more information about Medarex, visit its
website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com/
http://www.prnewswire.com/comp/108265.html/
CONTACT:
Laura S. Choi, Investor Relations, of
Medarex, Inc., +1-609-430-2880, x2216; or Jean Mantuano,
Corporate Communications (media), of Medarex, Inc.,
+1-609-430-2880, x2221
|
